Introducing the Oncotype DX Test
The Oncotype DX® Breast Recurrence Score™ is a multigene diagnostic test that determines the individual risk of cancer recurrence in early-stage invasive breast cancer and identifies patients with minimal, if any, likelihood of benefit, and patients with substantial likelihood of benefit from chemotherapy. The Oncotype DX Breast Recurrence Score reveals the underlying tumor biology to help guide treatment decisions.
The Oncotype DX test analyses the activity of 21 genes from the breast cancer tumor to provide an individual Breast Recurrence Score result, which is unique to the biology of a patient’s cancer.
The Oncotype DX Breast Recurrence Score should be used when the benefit of chemotherapy for a patient is uncertain. The test increases both the patient and her doctor’s confidence in treatment decisions.
Visit these pages for further information on the Oncotype DX Breast Recurrence Score, cancer-related terminology and FAQs.